Vasundhara Rasy.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE406F01010
  • NSEID:
  • BSEID: 538634
INR
115.95
-1.45 (-1.24%)
BSENSE

Mar 13

BSE+NSE Vol: 961

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

961 (-34.61%) Volume

Shareholding (Dec 2025)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

61.98%

Who are the top shareholders of the Vasundhara Rasy.?

06-Jun-2025

The top shareholder of Vasundhara Rasy is P & J Cretechem Private Limited, holding 61.98%, followed by Garg Leasing And Finance Private Limited at 3.55%, while individual investors own 30.05%. There are no mutual funds or foreign institutional investors in the company.

The top shareholders of Vasundhara Rasy include P & J Cretechem Private Limited, which holds the largest stake at 61.98%. The highest public shareholder is Garg Leasing And Finance Private Limited, with a holding of 3.55%. Additionally, individual investors collectively own 30.05% of the company. There are no mutual funds or foreign institutional investors currently holding shares in Vasundhara Rasy.

View full answer

how big is Vasundhara Rasy.?

06-Jun-2025

As of Jun 06, Vasundhara Rasayans Ltd has a market capitalization of 66.00 Cr, classifying it as a Micro Cap company, with recent net sales of 33.99 Cr and a net profit of 4.23 Cr. The latest balance sheet shows shareholder's funds of 31.94 Cr and total assets of 37.30 Cr.

Market Cap: As of Jun 06, Vasundhara Rasayans Ltd has a market capitalization of 66.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, the company reported Net Sales of 33.99 Cr and a Net Profit of 4.23 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: The Standalone balance sheet for the latest annual period, which is Mar'24, shows Shareholder's Funds of 31.94 Cr and Total Assets of 37.30 Cr.

View full answer

What does Vasundhara Rasy. do?

06-Jun-2025

Vasundhara Rasayans Ltd is a manufacturer and exporter of Antacids therapeutic category Active Pharmaceutical Ingredients in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of 8 Cr and a market cap of Rs 66 Cr.

Overview: <BR>Vasundhara Rasayans Ltd is a leading manufacturer and exporter of Antacids therapeutic category Active Pharmaceutical Ingredients, operating in the Pharmaceuticals & Biotechnology industry within the Micro Cap market segment.<BR><BR>History: <BR>Vasundhara Rasayans Ltd was incorporated in March 1987 and commenced operations in 1990 with an Antacid API facility. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 8 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 66 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 15.00 <BR>Industry P/E: 47 <BR>Dividend Yield: 0.98% <BR>Debt-Equity: -0.04 <BR>Return on Equity: 11.90% <BR>Price to Book: 1.82<BR><BR>Contact Details: <BR>Address: Shed No 42 Phase II IDA, Mallapur Hyderabad Telangana : 500076 <BR>Tel: 91-40-23437617/23437623 <BR>Email: info@vrlindia.in <BR>Website: http://www.vasundhararasayans.in

View full answer

Has Vasundhara Rasy. declared dividend?

06-Jun-2025

Vasundhara Rasayans Ltd has declared a 20% dividend, amounting to ₹2 per share, with an ex-date of September 23, 2024. While the stock has shown strong long-term gains, recent performance reflects negative returns in the short term, and the dividend yield is relatively low at 0.98%.

Vasundhara Rasayans Ltd has declared a 20% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 20%<BR>- Amount per share: 2<BR>- Ex-date: 23 Sep 24<BR><BR>Dividend Yield: 0.98%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -27.93%, with a dividend return of 0%, resulting in a total return of -27.93%.<BR><BR>Over the past year, the price return was -7.7%, the dividend return was 0.87%, leading to a total return of -6.83%.<BR><BR>In the 2-year period, the price return was 30.53%, the dividend return was 2.57%, culminating in a total return of 33.1%.<BR><BR>During the last 3 years, the price return was 77.1%, with a dividend return of 4.75%, resulting in a total return of 81.85%.<BR><BR>For the 4-year period, the price return was 112.13%, the dividend return was 5.39%, which led to a total return of 117.52%.<BR><BR>In the 5-year span, the price return was 479.66%, with a dividend return of 16.81%, resulting in a total return of 496.47%.<BR><BR>Overall, while Vasundhara Rasayans Ltd has declared a dividend, the recent total returns indicate a mixed performance, with significant gains over longer periods but negative returns in the short term. The dividend yield is relatively low, suggesting that while dividends are being paid, the stock may not be performing strongly in the short run.

View full answer

Who are the peers of the Vasundhara Rasy.?

03-Jun-2025

Vasundhara Rasy.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Vivo Bio Tech, Roopa Industries, Medi Caps, and Dipna Pharmachem. Its 1-year return is -9.07%, lower than Vivo Bio Tech's -5.81%, with average management risk and good capital structure.

Peers: The peers of Vasundhara Rasy. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Vivo Bio Tech, Roopa Industries, Medi Caps, and Dipna Pharmachem.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Vivo Bio Tech, Vasundhara Rasy., Medi Caps, and JFL Life. Below Average management risk is noted at Roopa Industries, and Dipna Pharmachem does not qualify. Growth is Excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Vivo Bio Tech, Vasundhara Rasy., Medi Caps, and the rest. Good growth is noted at Roopa Industries, while Dipna Pharmachem does not qualify. Capital Structure is Excellent at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, Good at Torrent Pharma and Vasundhara Rasy., while Average is found at Vivo Bio Tech and JFL Life, and Below Average at Roopa Industries and Medi Caps.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the lowest is Vivo Bio Tech at -5.81%. Vasundhara Rasy.'s 1-year return is -9.07%, which is lower than Vivo Bio Tech's. Additionally, the six-month return is negative for Vasundhara Rasy., Vivo Bio Tech, Medi Caps, and Torrent Pharma.

View full answer

What is the technical trend for Vasundhara Rasy.?

09-Jun-2025

As of May 23, 2025, Vasundhara Rasy's technical trend has shifted to a moderate bearish stance, supported by bearish signals from key indicators like the MACD, Bollinger Bands, and moving averages, along with significant underperformance compared to the Sensex.

As of 23 May 2025, the technical trend for Vasundhara Rasy has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this assessment include the weekly MACD and Bollinger Bands both indicating bearish conditions, along with daily moving averages also showing bearish signals. The KST is bearish on a weekly basis and mildly bearish monthly, while Dow Theory reflects a mildly bearish stance on the weekly and monthly time frames. The stock has underperformed significantly compared to the Sensex over various periods, particularly year-to-date and over the past year.

View full answer

Who are in the management team of Vasundhara Rasy.?

16-Jul-2025

As of March 2022, the management team of Vasundhara Rasy includes Sunil Jain Kumar, Sanjoy Kumar Jain, Rajesh Pokerna, Seema Jain, Manish Kumar Jain as executive directors, along with independent directors Pradeep Kumar Jain, Pravichandra Majumdar Popatlal, Rajiv Kakodkar, Manish Jain, and Ashish Kedia. This diverse team oversees the company's governance and strategic direction.

As of March 2022, the management team of Vasundhara Rasy includes the following individuals:<BR><BR>1. Sunil Jain Kumar - Executive Director / Whole Time Director<BR>2. Sanjoy Kumar Jain - Executive Director & Whole Time Director<BR>3. Rajesh Pokerna - Executive Director & Managing Director<BR>4. Seema Jain - Executive Director & Whole Time Director<BR>5. Pradeep Kumar Jain - Independent Non-Executive Director<BR>6. Pravichandra Majumdar Popatlal - Independent Non-Executive Director<BR>7. Rajiv Kakodkar - Independent Non-Executive Director<BR>8. Manish Jain - Independent Director<BR>9. Ashish Kedia - Independent Director<BR>10. Manish Kumar Jain - Whole-time Director<BR><BR>This team comprises a mix of executive and independent directors, contributing to the governance and strategic direction of the company.

View full answer

How has been the historical performance of Vasundhara Rasy.?

13-Nov-2025

Vasundhara Rasy has experienced fluctuating net sales and profits, peaking at 37.94 Cr in Mar'23 but declining to 33.99 Cr by Mar'25, alongside a decrease in profitability and negative cash flow trends. Despite an increase in total assets and liabilities, the company's operating profit margin and overall profitability have faced significant challenges.

Answer:<BR>The historical performance of Vasundhara Rasy shows a fluctuating trend in net sales and profits over the years, with a notable decline in recent periods.<BR><BR>Breakdown:<BR>Vasundhara Rasy's net sales peaked at 37.94 Cr in Mar'23 but fell to 33.99 Cr by Mar'25. The total operating income followed a similar trend, decreasing from 37.94 Cr in Mar'23 to 33.99 Cr in Mar'25. The raw material costs have remained relatively stable, with a slight increase from 15.53 Cr in Mar'24 to 15.63 Cr in Mar'25. Operating profit (PBDIT) also declined from 8.33 Cr in Mar'24 to 6.40 Cr in Mar'25, reflecting a decrease in operating profit margin from 17.26% to 11.92%. Profit before tax decreased from 7.90 Cr in Mar'24 to 5.77 Cr in Mar'25, while profit after tax dropped from 5.86 Cr to 4.25 Cr in the same period. The company's total assets increased from 37.30 Cr in Mar'24 to 43.07 Cr in Mar'25, alongside a rise in total liabilities from 37.30 Cr to 43.07 Cr. Cash flow from operating activities showed a negative trend, with a cash outflow of 5.00 Cr in Mar'25 compared to an inflow of 6.00 Cr in Mar'24. Overall, while Vasundhara Rasy has seen growth in total assets, its profitability and cash flow have faced challenges in recent years.

View full answer

Is Vasundhara Rasy. overvalued or undervalued?

05-Dec-2025

As of December 4, 2025, Vasundhara Rasy. is considered overvalued with a valuation grade of "expensive," a PE Ratio of 13.42, and a year-to-date return of -35.36%, significantly lagging behind its peers and the Sensex.

As of 4 December 2025, the valuation grade for Vasundhara Rasy. has moved from very expensive to expensive, indicating a shift in perception regarding its market valuation. The company is currently considered overvalued. Key ratios include a PE Ratio of 13.42, an EV to EBITDA of 14.79, and a ROE of 12.74%. <BR><BR>In comparison to peers, Vasundhara Rasy.'s PE Ratio is significantly lower than Solar Industries, which has a PE of 88.66, and Gujarat Fluoroch at 54.14. While Vasundhara Rasy. shows a PEG Ratio of 0.00, indicating no growth expectations, its current valuation does not align favorably with its peers in the Pharmaceuticals & Biotechnology sector. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -35.36% compared to the Sensex's 9.12%, further reinforcing the overvaluation narrative.

View full answer

Should I buy, sell or hold Vasundhara Rasy.?

18-Dec-2025

When is the next results date for Vasundhara Rasayans Ltd?

03-Feb-2026

The next results date for Vasundhara Rasayans Ltd is 10 February 2026.

The next results date for Vasundhara Rasayans Ltd is scheduled for 10 February 2026.

View full answer

Are Vasundhara Rasayans Ltd latest results good or bad?

11-Feb-2026

Vasundhara Rasayans Ltd's latest results show strong profit growth with a 261.40% increase in net profit to ₹2.06 crores and an improved operating margin of 24.04%. However, revenue declined by 9.82% year-on-year to ₹8.82 crores, indicating challenges despite the positive profit performance.

The latest results for Vasundhara Rasayans Ltd present a mixed picture. On one hand, the company reported a significant increase in net profit for Q2 FY26, reaching ₹2.06 crores, which is a remarkable 261.40% increase quarter-on-quarter. This improvement is accompanied by a strong operating margin of 24.04%, a substantial rise from just 4.23% in the previous quarter. <BR><BR>However, the revenue figures tell a different story. The company generated ₹8.82 crores in revenue for Q2 FY26, which represents a 9.82% decline compared to the same quarter last year. While there was a sequential growth of 16.67% from the previous quarter, the year-on-year drop raises concerns about the sustainability of this growth.<BR><BR>Overall, while the profit margins and operational efficiency have improved significantly, the decline in revenue indicates underlying challenges that the company faces. This combination of strong profit growth alongside stagnating revenue suggests that while there are positive aspects, there are also serious concerns that need to be addressed. Therefore, the results can be seen as good in terms of profitability but bad in terms of revenue growth, reflecting a complex situation for the company.

View full answer

Why is Vasundhara Rasayans Ltd falling/rising?

11-Mar-2026

As of 11-Mar, the stock price of Vasundhara Rasayans Ltd is at 115.15, reflecting a significant decline of 52.99% over the past year, with recent trading showing underperformance against its sector and bearish trends across multiple moving averages. Investor participation has decreased, further contributing to the stock's ongoing price drop.

As of 11-Mar, the stock price of Vasundhara Rasayans Ltd is falling, currently at 115.15, which reflects a decrease of 4.05 or 3.4%. This decline is evident in the stock's performance over various periods, with a 1-week drop of 4.04%, a 1-month decrease of 18.25%, and a year-to-date decline of 32.30%. Over the past year, the stock has fallen by 52.99%, contrasting sharply with the Sensex, which has increased by 3.73% in the same timeframe.<BR><BR>Today's trading performance indicates that the stock has underperformed its sector by 2.58%. It reached an intraday low of Rs 115, down 3.52%, and the weighted average price suggests that more volume was traded closer to this low price. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. <BR><BR>Investor participation has also decreased, with delivery volume on 10 March falling by 19.42% compared to the 5-day average. This decline in trading activity, coupled with the stock's overall negative performance metrics, contributes to the ongoing decrease in its price.

View full answer

Why is Vasundhara Rasayans Ltd falling/rising?

12-Mar-2026

As of 12-Mar, Vasundhara Rasayans Ltd's stock price is up to 117.40, reflecting a 1.95% increase today. Despite this short-term rise, the stock has seen significant declines over the past year and is trading below key moving averages, indicating a bearish trend.

As of 12-Mar, Vasundhara Rasayans Ltd is experiencing a rise in its stock price, currently at 117.40, with a change of 2.25 (1.95%) upward. This increase is notable as the stock opened with a gain of 2.48% today and reached an intraday high of Rs 124.2, which is a 7.86% increase. Additionally, the stock has outperformed its sector by 2.98% today.<BR><BR>However, despite this positive movement, the stock has shown a significant decline over longer periods, with a year-to-date drop of 30.98% and a one-year decline of 53.04%. The stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a longer-term bearish trend. Furthermore, there has been a notable decrease in investor participation, with delivery volume falling by 47.29% against the 5-day average.<BR><BR>In summary, while the stock is rising today, it is important to consider the broader context of its recent performance and declining investor interest.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Weak Long Term Fundamental Strength with a -6.46% CAGR growth in Operating Profits over the last 5 years

  • PBT LESS OI(Q) At Rs 0.30 cr has Fallen at -63.2% (vs previous 4Q average)
  • PAT(Q) At Rs 0.72 cr has Fallen at -36.4% (vs previous 4Q average)
  • NET SALES(Q) Lowest at Rs 7.45 cr
2

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 37 Cr (Micro Cap)

stock-summary
P/E

10.00

stock-summary
Industry P/E

38

stock-summary
Dividend Yield

1.69%

stock-summary
Debt Equity

-0.04

stock-summary
Return on Equity

10.69%

stock-summary
Price to Book

1.06

Revenue and Profits:
Net Sales:
7 Cr
(Quarterly Results - Dec 2025)
Net Profit:
1 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (1.69%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-37.61%
0%
-37.61%
6 Months
-40.99%
1.06%
-39.93%
1 Year
-52.28%
0.78%
-51.5%
2 Years
-36.93%
2.00%
-34.93%
3 Years
-21.1%
4.81%
-16.29%
4 Years
3.11%
5.65%
8.76%
5 Years
51.17%
11.24%
62.41%

Latest dividend: 2 per share ex-dividend date: Sep-19-2025

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Announcements stock-summary

Announcement under Regulation 30 (LODR)-Newspaper Publication

11-Feb-2026 | Source : BSE

Newspaper Advertisement pertaining to un-audited financial results of the Company for the quarter ended on December 31 2025

Board Meeting Outcome for Outcome Of The Board Meeting Held On 10.02.2026

10-Feb-2026 | Source : BSE

Board approved the Un-audited Financial Results of the Company for the quarter ended on 31st December 2025 and Limited Review Report

Financial Results For The Quarter Ended On 31.12.2025

10-Feb-2026 | Source : BSE

Approved Financial Results and Limited Review Report for the Quarter ended on 31.12.2025

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Vasundhara Rasayans Ltd has declared 20% dividend, ex-date: 19 Sep 25

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
7.83%
EBIT Growth (5y)
-6.46%
EBIT to Interest (avg)
3.96
Debt to EBITDA (avg)
0.48
Net Debt to Equity (avg)
-0.04
Sales to Capital Employed (avg)
1.13
Tax Ratio
26.64%
Dividend Payout Ratio
14.97%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
18.08%
ROE (avg)
14.84%

Valuation key factors

Factor
Value
P/E Ratio
10
Industry P/E
38
Price to Book Value
1.04
EV to EBIT
13.93
EV to EBITDA
11.96
EV to Capital Employed
1.04
EV to Sales
1.12
PEG Ratio
NA
Dividend Yield
1.72%
ROCE (Latest)
10.75%
ROE (Latest)
10.69%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

P & J Cretechem Private Limited (61.98%)

Highest Public shareholder

Garg Leasing And Finance Private Limited (3.55%)

Individual Investors Holdings

29.66%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -15.53% vs 16.67% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -65.05% vs 261.40% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.45",
          "val2": "8.82",
          "chgp": "-15.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.52",
          "val2": "2.12",
          "chgp": "-75.47%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.09",
          "chgp": "11.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.72",
          "val2": "2.06",
          "chgp": "-65.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "6.98%",
          "val2": "24.04%",
          "chgp": "-17.06%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is -5.92% vs -1.36% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 12.88% vs -0.43% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "16.38",
          "val2": "17.41",
          "chgp": "-5.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2.45",
          "val2": "2.47",
          "chgp": "-0.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.23",
          "val2": "0.13",
          "chgp": "76.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "2.63",
          "val2": "2.33",
          "chgp": "12.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "14.96%",
          "val2": "14.19%",
          "chgp": "0.77%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -9.15% vs 1.35% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -11.38% vs 1.61% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "23.83",
          "val2": "26.23",
          "chgp": "-9.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2.97",
          "val2": "4.04",
          "chgp": "-26.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.33",
          "val2": "0.19",
          "chgp": "73.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "3.35",
          "val2": "3.78",
          "chgp": "-11.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "12.46%",
          "val2": "15.40%",
          "chgp": "-2.94%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -8.18% vs -2.42% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -27.47% vs 4.83% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "33.99",
          "val2": "37.02",
          "chgp": "-8.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4.05",
          "val2": "6.39",
          "chgp": "-36.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.27",
          "val2": "0.17",
          "chgp": "58.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "4.25",
          "val2": "5.86",
          "chgp": "-27.47%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "11.92%",
          "val2": "17.26%",
          "chgp": "-5.34%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
7.45
8.82
-15.53%
Operating Profit (PBDIT) excl Other Income
0.52
2.12
-75.47%
Interest
0.10
0.09
11.11%
Exceptional Items
0.00
0.00
Standalone Net Profit
0.72
2.06
-65.05%
Operating Profit Margin (Excl OI)
6.98%
24.04%
-17.06%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is -15.53% vs 16.67% in Sep 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Dec 2025 is -65.05% vs 261.40% in Sep 2025

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
16.38
17.41
-5.92%
Operating Profit (PBDIT) excl Other Income
2.45
2.47
-0.81%
Interest
0.23
0.13
76.92%
Exceptional Items
0.00
0.00
Standalone Net Profit
2.63
2.33
12.88%
Operating Profit Margin (Excl OI)
14.96%
14.19%
0.77%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is -5.92% vs -1.36% in Sep 2024

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2025 is 12.88% vs -0.43% in Sep 2024

Nine Monthly Results Snapshot (Standalone) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
23.83
26.23
-9.15%
Operating Profit (PBDIT) excl Other Income
2.97
4.04
-26.49%
Interest
0.33
0.19
73.68%
Exceptional Items
0.00
0.00
Standalone Net Profit
3.35
3.78
-11.38%
Operating Profit Margin (Excl OI)
12.46%
15.40%
-2.94%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is -9.15% vs 1.35% in Dec 2024

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2025 is -11.38% vs 1.61% in Dec 2024

Annual Results Snapshot (Standalone) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
33.99
37.02
-8.18%
Operating Profit (PBDIT) excl Other Income
4.05
6.39
-36.62%
Interest
0.27
0.17
58.82%
Exceptional Items
0.00
0.00
Standalone Net Profit
4.25
5.86
-27.47%
Operating Profit Margin (Excl OI)
11.92%
17.26%
-5.34%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is -8.18% vs -2.42% in Mar 2024

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2025 is -27.47% vs 4.83% in Mar 2024

stock-summaryCompany CV
About Vasundhara Rasayans Ltd stock-summary
stock-summary
Vasundhara Rasayans Ltd
Micro Cap
Pharmaceuticals & Biotechnology
Vasundhara Rasayans Limited was incorporated in March, 1987. The Company is the leading manufacturer and exporter of Antacids therapeutic category of Active Pharmaceutical Ingredients with annual capacity of about 1500 MT of powder or its equivalent products. It started its operation in year 1990 with an Antacid API facility offering product in paste, powder and micronised grade of powder.
Company Coordinates stock-summary
Company Details
Shed No 42 Phase II IDA, Mallapur Hyderabad Telangana : 500076
stock-summary
Tel: 91-40-23437617/23437623
stock-summary
info@vrlindia.in
Registrar Details
Cil Securities Ltd , 214 Raghava Ratna Towers , Chirag Ali Lane, Abidas, Hyderabad